BACKGROUND: High rates of substance disorders in schizophrenia and other mental illnesses may reflect biological vulnerabilities to the addiction process. Interactions between addictive drug effects and mental illness involving circuits that generate motivated behavior may underpin this vulnerability. METHODS: We examined separate and combined effects of neonatal ventral hippocampal lesions (NVHLs)-a neurodevelopmental model of schizophrenia (vs. SHAM-operated control animals)--and a behaviorally sensitizing cocaine history (15 mg/kg/day x 5 days vs. saline injections) on acute cocaine-induced neural activation signaled by c-Fos expression. Stereological assessment of activation densities spanned six ventral to dorsal cortical-striatal compartments. RESULTS: Cortically, NVHLs showed hypoactivation and decreased volume of the ventral medial prefrontal cortex. In contrast, cocaine history was only expressed subcortically and as a hyperactivating effect in the dorsal striatum where significant NVHL-induced hyperactivation also emerged. Across all subjects and brain regions, only dorsal striatal activation was correlated with differences in sensitized locomotion. However, this activation was tightly correlated to a simple multiplicative function of ventral medial prefrontal hypoactivation and cocaine history-related increases in striatal activation. CONCLUSIONS: These findings suggest drug history and developmental temporal limbic abnormalities associated with prefrontal dysfunction produce compounding effects within cortical-striatal circuits as mechanistic basis for dual diagnosis. Copyright 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
BACKGROUND: High rates of substance disorders in schizophrenia and other mental illnesses may reflect biological vulnerabilities to the addiction process. Interactions between addictive drug effects and mental illness involving circuits that generate motivated behavior may underpin this vulnerability. METHODS: We examined separate and combined effects of neonatal ventral hippocampal lesions (NVHLs)-a neurodevelopmental model of schizophrenia (vs. SHAM-operated control animals)--and a behaviorally sensitizing cocaine history (15 mg/kg/day x 5 days vs. saline injections) on acute cocaine-induced neural activation signaled by c-Fos expression. Stereological assessment of activation densities spanned six ventral to dorsal cortical-striatal compartments. RESULTS: Cortically, NVHLs showed hypoactivation and decreased volume of the ventral medial prefrontal cortex. In contrast, cocaine history was only expressed subcortically and as a hyperactivating effect in the dorsal striatum where significant NVHL-induced hyperactivation also emerged. Across all subjects and brain regions, only dorsal striatal activation was correlated with differences in sensitized locomotion. However, this activation was tightly correlated to a simple multiplicative function of ventral medial prefrontal hypoactivation and cocaine history-related increases in striatal activation. CONCLUSIONS: These findings suggest drug history and developmental temporal limbic abnormalities associated with prefrontal dysfunction produce compounding effects within cortical-striatal circuits as mechanistic basis for dual diagnosis. Copyright 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
Authors: Nikos Makris; Gregory P Gasic; David N Kennedy; Steven M Hodge; Jonathan R Kaiser; Myung Joo Lee; Byoung Woo Kim; Anne J Blood; A Eden Evins; Larry J Seidman; Dan V Iosifescu; Sang Lee; Claudia Baxter; Roy H Perlis; Jordan W Smoller; Maurizio Fava; Hans C Breiter Journal: Neuron Date: 2008-10-09 Impact factor: 17.173
Authors: Neal R Swerdlow; Susan B Powell; Michelle R Breier; Samantha R Hines; Gregory A Light Journal: Neuropharmacology Date: 2013-06-26 Impact factor: 5.250
Authors: Leslie Hulvershorn; Tom Hummer; Yu-Chien Wu; Ralph Tarter; Parker Rea; Amit Anand; R Andrew Chambers; Peter Finn Journal: Brain Imaging Behav Date: 2018-02 Impact factor: 3.978
Authors: Jenifer L Vohs; R Andrew Chambers; Brian F O'Donnell; Giri P Krishnan; Sandra L Morzorati Journal: Int J Psychophysiol Date: 2012-04-12 Impact factor: 2.997
Authors: Vladimir M Pogorelov; Jun Nomura; Jongho Kim; Geetha Kannan; Yavuz Ayhan; Chunxia Yang; Yu Taniguchi; Bagrat Abazyan; Heather Valentine; Irina N Krasnova; Atsushi Kamiya; Jean Lud Cadet; Dean F Wong; Mikhail V Pletnikov Journal: Neuropharmacology Date: 2011-02-17 Impact factor: 5.250
Authors: R A Chambers; J N McClintick; A M Sentir; S A Berg; M Runyan; K H Choi; H J Edenberg Journal: Genes Brain Behav Date: 2013-06-22 Impact factor: 3.449
Authors: Amy A Herrold; Sandra L Kletzel; Brett C Harton; R Andrew Chambers; Neil Jordan; Theresa Louise-Bender Pape Journal: Neural Regen Res Date: 2014-10-01 Impact factor: 5.135
Authors: Kalyan N Rao; Alena M Sentir; Eric A Engleman; Richard L Bell; Leslie A Hulvershorn; Alan Breier; R Andrew Chambers Journal: Psychopharmacology (Berl) Date: 2016-09-17 Impact factor: 4.530
Authors: Sarah A Berg; Alena M Sentir; Benjamin S Cooley; Eric A Engleman; R Andrew Chambers Journal: Addict Biol Date: 2013-08-06 Impact factor: 4.280